Corvus Pharmaceuticals Statistics
Total Valuation
CRVS has a market cap or net worth of $321.93 million. The enterprise value is $280.63 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 64.26 million shares outstanding. The number of shares has increased by 18.45% in one year.
| Current Share Class | 64.26M |
| Shares Outstanding | 64.26M |
| Shares Change (YoY) | +18.45% |
| Shares Change (QoQ) | +11.71% |
| Owned by Insiders (%) | 3.44% |
| Owned by Institutions (%) | 15.25% |
| Float | 41.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 25.27 |
| P/TBV Ratio | 25.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.92 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -200.48% and return on invested capital (ROIC) is -53.35%.
| Return on Equity (ROE) | -200.48% |
| Return on Assets (ROA) | -28.30% |
| Return on Capital (ROIC) | -53.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.03M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +140.87% in the last 52 weeks. The beta is 1.07, so CRVS's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +140.87% |
| 50-Day Moving Average | 7.17 |
| 200-Day Moving Average | 4.40 |
| Relative Strength Index (RSI) | 37.72 |
| Average Volume (20 Days) | 1,611,644 |
Short Selling Information
The latest short interest is 5.43 million, so 8.45% of the outstanding shares have been sold short.
| Short Interest | 5.43M |
| Short Previous Month | 4.31M |
| Short % of Shares Out | 8.45% |
| Short % of Float | 13.01% |
| Short Ratio (days to cover) | 3.82 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.07M |
| Pretax Income | -22.62M |
| Net Income | -56.83M |
| EBITDA | -24.98M |
| EBIT | -25.07M |
| Earnings Per Share (EPS) | -$1.01 |
Full Income StatementBalance Sheet
The company has $41.65 million in cash and $354,000 in debt, giving a net cash position of $41.30 million or $0.64 per share.
| Cash & Cash Equivalents | 41.65M |
| Total Debt | 354,000 |
| Net Cash | 41.30M |
| Net Cash Per Share | $0.64 |
| Equity (Book Value) | 12.41M |
| Book Value Per Share | 0.20 |
| Working Capital | -3.49M |
Full Balance SheetCash Flow
| Operating Cash Flow | -22.13M |
| Capital Expenditures | n/a |
| Free Cash Flow | -22.13M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |